Welcome to our dedicated page for MiMedx Group news (Ticker: MDXG), a resource for investors and traders seeking the latest updates and insights on MiMedx Group stock.
MiMedx Group, Inc. (NASDAQ: MDXG) is a pioneer in the field of advanced wound care and therapeutic biologics. The company specializes in developing and distributing human placental tissue allografts utilizing patent-protected processes. With a cornerstone methodology known as the PURION® Process, MiMedx ensures the production of high-quality allografts via aseptic processing techniques and terminal sterilization.
Having supplied over two million allografts through direct and consignment shipments, MiMedx is a trusted name in the healthcare sector. The company’s product range includes EpiFix for external use and AmnioFix for internal applications, alongside other innovative products such as AmnioCord, AmnioFill, EpiBurn, and EpiCord. Additionally, MiMedx markets allografts for ophthalmic surgery and dental applications through third-party licenses.
MiMedx is dedicated to transforming wound care in sectors like burn treatment, surgical procedures, sports medicine, and orthopedics. By combining its extensive portfolio with strategic initiatives, such as its recent exclusive partnership with Regenity for a 510(k) cleared, bovine-derived collagen matrix, the company aims to enhance its competitive edge and expand its market reach.
Financially, MiMedx has shown impressive growth. For 2023, the company reported net sales of $321 million, reflecting a 20% increase from the previous year. Strategically, new credit facilities have been secured to bolster financial flexibility. The company expects low double-digit net sales growth for 2024 and an adjusted EBITDA margin exceeding 20%.
Despite facing regulatory challenges, such as the FDA’s stance on the AXIOFILL product, MiMedx continues to thrive. The company is actively engaging with the FDA while maintaining the product in the market. This resilience underscores MiMedx’s commitment to compliance and innovation in providing safe and effective products.
The company’s vision is to be the leading global provider of healing solutions through relentless innovation, aiming to restore quality of life for patients. For more information, visit www.mimedx.com.
MiMedx Group has published a peer-reviewed study in the Journal of Investigative Dermatology, focusing on its Purion processed dehydrated human amnion/chorion membrane (dHACM). The research investigates the potential of dHACM to combat excessive fibrosis, affecting over 100 million people globally. Findings indicate that dHACM disrupts the TGF-β1 signaling pathway, regulating fibrotic activity and reducing pathological scar formation. MiMedx's CEO emphasized the continuous R&D investments to enhance understanding and application of their amniotic tissue technologies.
MIMEDX Group, Inc. (Nasdaq: MDXG) has received regulatory approval from the Japanese Ministry of Health for its EPIFIX allograft, allowing it to market this product in Japan. EPIFIX is designed to aid the healing of chronic wounds like diabetic foot ulcers and venous leg ulcers. The approval is projected to benefit up to 100,000 new patients annually. MIMEDX is now focusing on establishing reimbursement and distribution networks, aiming for EPIFIX availability in early 2022.
MIMEDX Group, an industry leader in regenerative medicine using amniotic tissue, announced that key executives will participate in a fireside chat at the Jefferies Virtual Healthcare Conference.
Date: June 4, 2021
Time: 2:00 PM ET
Webcast Link: Join Here
MIMEDX specializes in developing placental tissue allografts for healthcare sectors, processing tissues through proprietary methods and maintaining high production standards.
MIMEDX Group, Inc. (NASDAQ: MDXG) has extended the deadline for shareholders to pre-register for the 2021 Annual Meeting to May 26, 2021, at 10:00 a.m. Eastern Time. The virtual meeting is scheduled for May 27, 2021, at 10:00 a.m. Eastern. Shareholders are advised to pre-register to participate. Details on pre-registration can be found in the Company's definitive proxy statement or online at www.votemimedx.com. Shareholders eligible to vote must be on record as of April 16, 2021.
MIMEDX Group, a leader in regenerative medicine utilizing amniotic tissue, announced that CEO Timothy R. Wright and CFO Peter M. Carlson will participate in two upcoming virtual investor conferences. The first event is the Bank of America Securities 2021 Virtual Health Care Conference on May 13, 2021, at 2:45 PM ET, and the second is the Canaccord Genuity Virtual Musculoskeletal Conference on May 20, 2021, at 10:00 AM ET. Interested investors can access the webcasts through the company’s website and contact their representatives for meetings.
MIMEDX Group, Inc. (Nasdaq: MDXG) announced a collaborative agreement with the Wake Forest Institute for Regenerative Medicine to enhance scientific evidence supporting amniotic tissue therapies. This partnership aims to advance regenerative science and innovative biologics, with a focus on understanding product mechanisms and potential therapeutic targets. CEO Timothy R. Wright emphasized the importance of peer-reviewed data for patient care, while WFIRM's Dr. Anthony Atala expressed enthusiasm for the collaboration. MIMEDX continues to lead in amniotic tissue science and aims to develop next-generation therapies.
Prescience Point Capital Management has withdrawn its nominees for the MiMedx Group, Inc. (NASDAQ: MDXG) Board of Directors ahead of the Annual Meeting set for May 27, 2021. The firm believes its activism has led to significant improvements in corporate governance and a focus on enhancing shareholder value. Key governance proposals include lowering the special meeting ownership threshold from 50% to 25% and de-staggering the Board. Prescience Point remains a long-term stakeholder, emphasizing that MiMedx shares are undervalued, and encouraging shareholders to support the proposed changes.
MIMEDX Group, Inc. (NASDAQ: MDXG) urges shareholders to scrutinize Prescience Point's motives in its proxy fight for board influence. The Company highlights concerns over Prescience Point's trading practices, suggesting self-serving interests, and questions the qualifications of its nominees. MIMEDX emphasizes its turnaround success since appointing CEO Timothy R. Wright, noting a 237% increase in stock value and renewed credibility with the FDA. Shareholders are encouraged to vote for MIMEDX’s qualified directors at the upcoming Annual Meeting on May 27, 2021, to protect their investments.
MIMEDX Group, Inc. (NASDAQ: MDXG) urges shareholders to vote for its four director nominees at the virtual annual meeting on May 27, 2021. The company highlights a 237% stock price increase since CEO Timothy Wright's appointment in May 2019.
Key achievements under new management include the completion of five years of financial restatements, relisting on NASDAQ, resolution of litigation, and securing reimbursement coverage from major payors. MIMEDX aims to leverage opportunities in the regenerative medicine sector for sustainable growth and shareholder value.
FAQ
What is the current stock price of MiMedx Group (MDXG)?
What is the market cap of MiMedx Group (MDXG)?
What does MiMedx Group, Inc. specialize in?
What are MiMedx's key products?
How has MiMedx performed financially in 2023?
What is the PURION® Process?
How does MiMedx handle regulatory challenges?
What new collaborations has MiMedx recently announced?
What is MiMedx's vision?
Where can I find more information about MiMedx?
What markets does MiMedx target?
Who can I contact for investor relations at MiMedx?
